Поражение почек при туберозном склерозе

Туберозный склероз — редкое генетическое заболевание, характеризующееся развитием доброкачественных опухолей в различных органах, включая почки. Поражение почек при туберозном склерозе наиболее часто представлено ангиомиолипомами и кистами, которые могут приводить к различным осложнениям, таким как кровотечения, почечная недостаточность и злокачественная трансформация. В представленной обзорной статье рассматриваются современные представления о патогенезе, клинических проявлениях, диагностике и методах лечения поражения почек при туберозном склерозе, а также перспективы дальнейших исследований в данной области.

1. Borkowska J., Schwartz R.A., Kotulska K., Jozwiak S. Tuberous sclerosis complex: tumors and tumorigenesis. Int J Dermatol. 2011; 50(1): 13–20. DOI: 10.1111/j.1365-4632.2010.04727.x

2. Huang J., Manning B.D. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008; 412(2): 179–190. DOI: 10.1042/BJ20080281

3. Морозов С.Л, Пирузиева О.Р., Дорофеева М.Ю., Тарасова О.В., Длин В.В. Ангиомиолипомы почек у детей при туберозном склерозе — современное состояние проблемы. Практическая Медицина [Internet]. 2022; 20(2): 45–49 DOI: 10.32000/2072-1757-2022-2-45-49.

4. Curatolo P., Bombardieri R., Jozwiak S. Tuberous sclerosis. The Lancet. 2008; 372(9639):657–668. DOI: 10.1016/S0140-6736(08)61279-9

5. Northrup H., Krueger D., Northrup H., Krueger D.A., Roberds S., Smith K., et al. Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology 2013; 49(4): 243–254. DOI: 10.1016/j.pediatrneurol.2013.08.001

6. van Slegtenhorst M., de Hoogt R., Hermans C., Nellist M., Janssen B., Verhoef S., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997; 277(5327):805–808. DOI: 10.1126/science.277.5327.805

7. Northrup H., Aronow M.E., Bebin E.M., Bissler J., Darling T.N., de Vries P.J., et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol. 2021; 123: 50–66. DOI: 10.1016/j.pediatrneurol.2021.07.011

8. O’Callaghan F.J., Noakes M.J., Martyn C.N., Osborne J.P. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int. 2004; 94(6): 853–857. DOI: 10.1111/j.1464-410X.2004.05046.x

9. Martignoni G., Pea M., Rocca P.C., Bonetti F. Renal pathology in the tuberous sclerosis complex. Pathology. 2003; 35(6): 505–512. DOI: 10.1080/00313020310001619136

10. Zöllner J.P., Franz D.N., Hertzberg C., Nabbout R., Rosenow F., Sauter M., et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). Orphanet J Rare dis. 2020; 15(1): 23. DOI: 10.1186/s13023-019-1258-3

11. Bissler J.J., Kingswood J.C. Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review. Ther Adv Urol. 2016; 8(4): 279–290. DOI: 10.1177/1756287216641353

12. Mekahli D., Müller R-U., Marlais M., Wlodkowski T., Haeberle S., De Argumedo M.L., et al. Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group. Nat Rev Nephrol. 2024; 20(6): 402–420. DOI: 10.1038/s41581-024-00818-0

13. Stillwell T.J., Gomez M.R., Kelalis P.P. Renal lesions in tuberous sclerosis. J Urol. 1987; 138(3): 477–481. DOI: 10.1016/s0022-5347(17)43234-4

14. Подольная М.А., Кобринский Б.А., Белоусова Е.Д., Дорофеева М.Ю., Пивоварова (Горейко) А.М. Регистр больных туберозным склерозом RU 2017620527. 2017

15. Алтунина Г.Е., Балаян И.Г., Белоусова Е.Д., Березницкая В.В., Божко О.В., Верченко Е.Г., и др. Туберозный склероз. Диагностика и лечение. Адаре. 2017: 288.

16. Морозов С.Л., Пирузиева О.Р., Дорофеева М.Ю., Катышева О.В., Тарасова О.В., Сахарова Е.С. и др. Проблемы поликистоза почек у детей с туберозным склерозом на современном этапе. Медицинский Оппонент. 2022;(3 (19)):45–50.

17. Kingswood J.C., d’Augères G.B., Belousova E., Ferreira J.C., Carter T., Castellana R. et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA) — baseline data on 2093 patients. Orphanet J Rare Dis. 2017; 12: 2. DOI: 10.1186/s13023-016-0553-5

18. Rouvière O., Nivet H., Grenier N., Zini L., Lechevallier E. Kidney damage due to tuberous sclerosis complex: management recommendations. Diagn Interv Imaging. 2013; 94(3): 225–237. DOI: 10.1016/j.diii.2013.01.003

19. Bains L., Bhatia R., Lal P., Bhagria G. Giant bilateral angiomyolipoma of the kidney. Ann R Coll Surg Engl. 2021. 103(6):e184-e188. DOI: 10.1308/rcsann.2020.7036

20. Dabora S.L., Jozwiak S., Franz D.N., Roberts P.S., Nieto A., Chung J. et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001; 68(1): 64–80. DOI: 10.1086/316951

21. Budde K., Gaedeke J. Tuberous Sclerosis Complex–Associated Angiomyolipomas: Focus on mTOR Inhibition. American Journal of Kidney Diseases. 2012; 59(2): 276–283. DOI: 10.1053/j.ajkd.2011.10.013

22. Kingswood J.C., Belousova E., Benedik M.P., Carter T., Cottin V., Curatolo P. et al. Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness. Nephrol Dial Transplant. 2019; 34(3): 502–508. DOI: 10.1093/ndt/gfy063

23. Johnson S.R., Cordier J.F., Lazor R., Cottin V., Costabel U., Harari S. et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010; 35(1): 14–26. DOI: 10.1183/09031936.00076209

24. Muller A., Rouvière O. Renal artery embolization—indications, technical approaches and outcomes. Nat Rev Nephrol. 2015; 11(5): 288–301. DOI: 10.1038/nrneph.2014.231

25. Krueger D.A., Northrup H., Northrup H., Krueger D.A., Roberds S., Smith K. et al. Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. PediatricNeurology.2013; 49(4): 255–265

26. Siroky B.J., Czyzyk-Krzeska M.F., Bissler J.J. Renal involvement in tuberous sclerosis complex and von Hippel-Lindau disease: shared disease mechanisms? Nat Clin Pract Nephrol. 2009; 5(3): 143–156. DOI: 10.1038/ncpneph1032

27. Henderson R.J., Germany R., Peavy P.W., Eastham J.A., Venable D.D. Fat density in renal cell carcinoma: demonstration with computerized tomography. J Urol. 1997; 157(4): 1347–1348

28. Морозов С.Л., Пирузиева О.Р., Длин В.В. Эффективность таргетной терапии поражения почек при туберозном склерозе у ребенка (клинический случай). Нефрология. 2021; 25(4): 90–94. DOI: 10.36485/1561-6274-2021-25-4-90-94.

29. Napolioni V., Moavero R., Curatolo P. Recent advances in neurobiology of Tuberous Sclerosis Complex. Brain and Development. 2009; 31(2): 104–113. DOI: 10.1016/j.brain-dev.2008.09.013

30. Siroky B.J., Yin H., Bissler J.J. Clinical and Molecular Insights into Tuberous Sclerosis Complex Renal Disease. Pediatr Nephrol. 2011; 26(6): 839–852. DOI: 10.1007/s00467-010-1689-5

31. Magaki S.D., Vinters H.V. Tuberous Sclerosis Complex. In: Developmental Neuropathology. Editors Adle-Biassette H., Harding B.N., Golden J. Wiley; 2018; 117–131

32. Игнатова М.С. Кистозы почек у детей с позиций цилиопатий. Педиатрия. Журнал им. Г.Н. Сперанского. 2012; 91(3): 110–116

33. Kleymenova E., Ibraghimov-Beskrovnaya O., Kugoh H., Everitt J., Xu H., Kiguchi K., et al. Tuberin-Dependent Membrane Localization of Polycystin-1. Molecular Cell. 2001; 7(4): 823–832. DOI: 10.1016/S1097-2765(01)00226-X

34. Kingswood J.C., Belousova E., Benedik M.P., Carter T., Cottin V., Curatolo P. et al. Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas. Front. Neurol. 2020; 11: 972. DOI: 10.3389/fneur.2020.00972

35. Nelson C.P., Sanda M.G. Contemporary diagnosis and management of renal angiomyolipoma. J Urol. 2002; 168(4 Pt 1):1315–1325. DOI: 10.1016/S0022-5347(05)64440-0

36. Sooriakumaran P., Gibbs P., Coughlin G., Attard V., Elmslie F., Kingswood C. et al. Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated. BJU Int. 2010; 105(1): 101–106. DOI: 10.1111/j.1464-410X.2009.08649.x

37. Uysal S.P., Şahin M. Tuberous sclerosis: a review of the past, present, and future. Turk J Med Sci. 2020; 50(SI-2):1665–1676. DOI: 10.3906/sag-2002-133

38. Zoncu R., Bar-Peled L., Efeyan A., Wang S., Sancak Y., Sabatini D.M. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-AT-Pase. Science. 2011; 334(6056):678–683. DOI: 10.1126/science.1207056

39. Franz D.N., Belousova E., Sparagana S., Bebin E.M., Frost M., Kuperman R. et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 2014; 15(13): 1513–1520. DOI: 10.1016/S1470-2045(14)70489-9

40. Bissler J.J., Kingswood J.C., Radzikowska E., Zonnenberg B.A., Frost M., Belousova E. et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013; 381(9869):817–824. DOI: 10.1016/S0140-6736(12)61767-X

41. Bissler J.J., Budde K., Sauter M., Franz D.N., Zonnenberg B.A., Frost M.D. et al. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. Nephrol Dial Transplant. 2019; 34(6): 1000–1008. DOI: 10.1093/ndt/gfy132

42. Janssens P., Van Hoeve K., De Waele L., De Rechter S., Claes K.J., Van de Perre E. et al. Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study. Pediatr Nephrol. 2018; 33(11): 2085–2093. DOI: 10.1007/s00467-018-4003-6

43. Skrzypczyk P., Wabik A.M., Szyszka M., Józwiak S., Bombiński P., Jakimów-Kostrzewa A. et al. Early Vascular Aging in Children With Tuberous Sclerosis Complex. Front Pediatr. 2021; 9: 767394. DOI: 10.3389/fped.2021.767394

44. Massella L., Mekahli D., Paripović D., Prikhodina L., Godefroid N., Niemirska A. et al. Prevalence of Hypertension in Children with Early-Stage ADPKD. Clin J Am Soc Nephrol. 2018; 13(6): 874–883. DOI: 10.2215/CJN.11401017

45. Sugiura H., Shimada T., Moriya-Ito K., Goto J-I., Fujiwara H., Ishii R. et al. A Farnesyltransferase Inhibitor Restores Cognitive Deficits in Tsc2+/– Mice through Inhibition of Rheb1. J. Neurosci. 2022; 42(12): 2598–2612. DOI: 10.1523/JNEU-ROSCI.0449-21.2022

46. Muroga C., Yokoyama H., Kinoshita R., Fujimori D., Yamada Y., Okanishi T. et al. A child with TSC2/PKD1 contiguous gene deletion syndrome successfully treated with tolvaptan for rapidly enlarging renal cysts. CEN Case Rep. 2024; 13(5): 351–355. DOI: 10.1007/s13730-024-00854-6